Our focus is on making a measurable difference in global health.

MediBeacon is a medical technology company focused on developing fluorescent tracer agents and transdermal detection technology to help provide vital and actionable measurement of organ function.


In 2015, Pansend Life Sciences of HC2 Holdings, Inc. (NYSE MKT: HCHC) became the largest equity investor in MediBeacon.


In 2019, MediBeacon entered into a $30 million investment and exclusive commercialization partnership in Greater China with Huadong Medicine Co., Ltd. Huadong is a leading Chinese-based pharmaceutical company listed on the Shenzhen Stock Exchange.